The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery
Open Access
- 7 November 2008
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 323
- https://doi.org/10.1186/1471-2407-8-323
Abstract
Backgrounds Prognostic factors are defined as biological or clinical measurement associated with overall survival and/or disease-free survival. Previous studies have shown that patients with estrogen receptor (ER) positive cancers have a better prognosis than patients whose cancers do not have these receptors. Methods This study investigated the assessment of variables in defining prognosis of 742 breast cancer women with pathological stage (pTNM) I-III diagnosed between 1980 and 2005 at the Kyoto University Hospital in Japan, by age, clinical stage (cTNM), pTNM, the numbers of positive lymph nodes (pN), and ER status. Results Multivariate analysis demonstrated that pTNM and ER status were the independent prognostic factors for overall survival, and that pTNM and pN were the independent prognostic factors for disease-free survival. For the 0- to 2-year interval, the hazard of recurrence was higher for the ER-negative patients than the ER-positive patients, and beyond 3 years the hazard was higher for ER-positive patients. Conclusion The present study confirmed the previous reports which showed favorable prognosis of the patients with lesser pTNM or positive ER status. A reversal of recurrence hazard rate between ER positive and negative breast cancer patients beyond 3 years after operation was detected. The fact may indicate the importance of long term adjuvant hormone therapy for ER positive cancer patients.Keywords
This publication has 11 references indexed in Scilit:
- Changes in survival during the past two decades for breast cancer at the Kyoto University HospitalEuropean Journal of Surgical Oncology, 2007
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007Annals of Oncology, 2007
- Randomization in substance abuse clinical trialsSubstance Abuse Treatment, Prevention, and Policy, 2006
- Adjuvant endocrine therapies for pre-/perimenopausal womenThe Breast, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- The best use of adjuvant endocrine treatmentsThe Breast, 2003
- Prognostic factors in clinical decision makingCancer, 2001
- Tamoxifen: the Long and Short of ItJNCI Journal of the National Cancer Institute, 1996
- Annual hazard rates of recurrence for breast cancer after primary therapy.Journal of Clinical Oncology, 1996
- Do we really need prognostic factors for breast cancer?Breast Cancer Research and Treatment, 1994